Your session is about to expire
← Back to Search
Immunotherapy Combinations for Esophageal Cancer
Study Summary
This trial is designed to study the safety and effectiveness of immunotherapy-based treatment combinations in patients with gastric or esophageal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition is not gastric cancer.I haven't had cancer other than in my stomach or where my stomach meets my esophagus in the last 2 years.I have brain metastases that are untreated or getting worse.I have only had esophageal cancer or a low-risk cancer in the past 2 years.I agree to either not have sex or use birth control, and not donate sperm during the trial.My blood and organs are functioning well.I haven't had any serious wounds, ulcers, or fractures in the last 28 days.I have not had any serious gut issues like perforations or abnormal connections in the last 6 months.I have a history of serious bowel problems or surgeries.My blood pressure is high (over 150/90) despite taking medication.I am on long-term medication for pain or inflammation that affects blood clotting.I have not had a severe infection in the last 4 weeks.I have a serious heart condition.I have esophageal cancer with no prior systemic treatment, or it spread 6+ months after my last chemo.My cancer is advanced and cannot be surgically removed, and it's either in my stomach or where my stomach meets my esophagus.I am 18 years old or older.I am fully active or can carry out light work.My esophageal cancer is confirmed and has spread or is very advanced.My esophagus cancer is confirmed and is either advanced or has spread.I have esophageal cancer with no prior systemic treatment, or it spread 6+ months after my last chemo. My cancer does not show HER2.I have high calcium levels in my blood that aren't controlled or cause symptoms.I have a history of specific lung conditions or signs of lung inflammation on a recent CT scan.I have a condition that causes significant bleeding.I have had a previous transplant of stem cells or an organ.I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.I am currently on blood thinners like warfarin or heparin for treatment.I do not have esophageal cancer.I am at high risk for developing an esophageal fistula.I have active tuberculosis.I haven't had major heart problems or unstable heart conditions in the last 3 months.I have been diagnosed with gastric cancer.I agree to not have sex or use birth control and not donate sperm.My gastric cancer is HER2-negative.I can take care of myself and am up and about more than half of my waking hours.I am 18 years old or older.I am able to care for myself and perform daily activities.I have had lung conditions like pulmonary fibrosis or pneumonitis, or my CT scan shows active pneumonitis.My condition is esophageal cancer.I agree to either not have sex or use birth control, and not donate sperm.I am fully active or can carry out light work.I have had cancer spread to the lining of my brain and spinal cord.My gastric cancer is HER2-negative.My recent blood and organ function tests are within normal ranges.I agree to either not have sex or use birth control, and not donate sperm while on treatment.My blood and organs are functioning well.I have brain metastases that are untreated or getting worse.My cancer is advanced and cannot be removed by surgery.I can provide a tumor sample for testing.My recent blood tests show my organs are functioning well.I can provide a tumor sample for PD-L1 and TIGIT testing.
- Group 1: 2L-4: Atezo + Linagliptin (Gastric Cancer)
- Group 2: 2L-3: Atezo + BL-8040 (Gastric Cancer)
- Group 3: 1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)
- Group 4: 1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)
- Group 5: 1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)
- Group 6: 1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)
- Group 7: 2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)
- Group 8: 1L-Control: mFOLFOX6 (Gastric Cancer)
- Group 9: 1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)
- Group 10: 1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)
- Group 11: 2L-2: Atezo + PEGPH20 (Gastric Cancer)
- Group 12: 2L-1: Atezo + Cobi (Gastric Cancer)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many healthcare centers are presently engaging in this clinical trial?
"This medical investigation is being conducted at several sites including: Froedtert and The Medical College of Wisconsin in Milwaukee, UCLA Jonsson Comprehensive Cancer Center in Los Angeles, as well University of Kentucky in Lexington."
To what extent is participation in this research endeavor being sought after?
"In order to execute this clinical trial, 410 eligible patients need to be recruited. The two main sites for recruitment are Froedtert and The Medical College of Wisconsin in Milwaukee, WI and UCLA Jonsson Comprehensive Cancer Center in Los Angeles, CA."
Is this research initiative currently enrolling participants?
"Yes, that is accurate. The information on clinicaltrials.gov reveals that this experiment, which was initially announced on October 13th 2017, is currently in the process of recruitment and requires 410 subjects from 5 distinct locations."
For what ailments is Atezolizumab regularly prescribed?
"Atezolizumab is a renowned therapeutic agent for metastatic bladder cancer and has been tested to treat other malignancies such as inflammatory breast cancer (IBC), advanced testicular cancer, and small cell lung cancer (SCLC)."
What further investigations have been undertaken concerning the efficacy of Atezolizumab?
"Currently, we observe 2087 active studies concerning Atezolizumab, with 621 trials in their terminal stage. As the majority of these research efforts are conducted at sites in Guangzhou, Guangdong province, there exists a total of 109624 locations that are engaged in tests for this medication."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger